Aldosterone Synthase Inhibitors: A Revival for Treatment of Renal and Cardiovascular Diseases - Takeaways - MDSpire

Aldosterone Synthase Inhibitors: A Revival for Treatment of Renal and Cardiovascular Diseases

  • By

  • Michel Azizi

  • Julien Riancho

  • Laurence Amar

  • December 4, 2024

  • 0 min

Share

  • 1

    Inappropriate aldosterone excess contributes to various cardiovascular and renal diseases, necessitating effective treatment options.

  • 2

    Mineralocorticoid receptor antagonists (MRAs) like spironolactone and eplerenone are commonly used but have limitations due to side effects and tolerability.

  • 3

    Aldosterone synthase inhibitors (ASIs) are emerging as potential alternatives to MRAs, showing promise in reducing aldosterone production without affecting cortisol.

  • 4

    Early phase II trials indicate that ASIs can lower blood pressure and urinary albumin excretion in patients with hypertension and chronic kidney disease.

  • 5

    Further long-term studies are needed to assess the efficacy of ASIs in improving cardiovascular outcomes and kidney disease progression.

Original Source(s)

Aldosterone Synthase Inhibitors: A Revival for Treatment of Renal and Cardiovascular Diseases

  • by Michel Azizi, Julien Riancho, Laurence Amar

  • December 4, 2024

Related Content

Multidisease Detection from Fundus Imaging

Researchers in China create AI framework aimed at using retinal imaging to screen for multiple systemic diseases

  • June 8, 2026

  • 3 min
Global Trends and Research Topics in Gastric Bypass Clinical Trials: A Bibliometric Analysis and Latent Dirichlet Allocation (LDA) Study

The triglyceride-glucose–waist-to-height ratio is the strongest predictor of reduced kidney function in elderly hypertensive patients